489 related articles for article (PubMed ID: 30463916)
1. Hepatocyte Notch activation induces liver fibrosis in nonalcoholic steatohepatitis.
Zhu C; Kim K; Wang X; Bartolome A; Salomao M; Dongiovanni P; Meroni M; Graham MJ; Yates KP; Diehl AM; Schwabe RF; Tabas I; Valenti L; Lavine JE; Pajvani UB
Sci Transl Med; 2018 Nov; 10(468):. PubMed ID: 30463916
[TBL] [Abstract][Full Text] [Related]
2. The Annexin A2-Notch regulatory loop in hepatocytes promotes liver fibrosis in NAFLD by increasing osteopontin expression.
Wang G; Duan J; Pu G; Ye C; Li Y; Xiu W; Xu J; Liu B; Zhu Y; Wang C
Biochim Biophys Acta Mol Basis Dis; 2022 Aug; 1868(8):166413. PubMed ID: 35413401
[TBL] [Abstract][Full Text] [Related]
3. Hepatocyte TLR4 triggers inter-hepatocyte Jagged1/Notch signaling to determine NASH-induced fibrosis.
Yu J; Zhu C; Wang X; Kim K; Bartolome A; Dongiovanni P; Yates KP; Valenti L; Carrer M; Sadowski T; Qiang L; Tabas I; Lavine JE; Pajvani UB
Sci Transl Med; 2021 Jun; 13(599):. PubMed ID: 34162749
[TBL] [Abstract][Full Text] [Related]
4. The transcription factor c-Jun/AP-1 promotes liver fibrosis during non-alcoholic steatohepatitis by regulating Osteopontin expression.
Schulien I; Hockenjos B; Schmitt-Graeff A; Perdekamp MG; Follo M; Thimme R; Hasselblatt P
Cell Death Differ; 2019 Sep; 26(9):1688-1699. PubMed ID: 30778201
[TBL] [Abstract][Full Text] [Related]
5. Osteopontin is a proximal effector of leptin-mediated non-alcoholic steatohepatitis (NASH) fibrosis.
Coombes JD; Choi SS; Swiderska-Syn M; Manka P; Reid DT; Palma E; Briones-Orta MA; Xie G; Younis R; Kitamura N; Della Peruta M; Bitencourt S; Dollé L; Oo YH; Mi Z; Kuo PC; Williams R; Chokshi S; Canbay A; Claridge LC; Eksteen B; Diehl AM; Syn WK
Biochim Biophys Acta; 2016 Jan; 1862(1):135-44. PubMed ID: 26529285
[TBL] [Abstract][Full Text] [Related]
6. Osteopontin is induced by hedgehog pathway activation and promotes fibrosis progression in nonalcoholic steatohepatitis.
Syn WK; Choi SS; Liaskou E; Karaca GF; Agboola KM; Oo YH; Mi Z; Pereira TA; Zdanowicz M; Malladi P; Chen Y; Moylan C; Jung Y; Bhattacharya SD; Teaberry V; Omenetti A; Abdelmalek MF; Guy CD; Adams DH; Kuo PC; Michelotti GA; Whitington PF; Diehl AM
Hepatology; 2011 Jan; 53(1):106-15. PubMed ID: 20967826
[TBL] [Abstract][Full Text] [Related]
7. Hepatocyte TAZ/WWTR1 Promotes Inflammation and Fibrosis in Nonalcoholic Steatohepatitis.
Wang X; Zheng Z; Caviglia JM; Corey KE; Herfel TM; Cai B; Masia R; Chung RT; Lefkowitch JH; Schwabe RF; Tabas I
Cell Metab; 2016 Dec; 24(6):848-862. PubMed ID: 28068223
[TBL] [Abstract][Full Text] [Related]
8. Growth differentiation factor 15 ameliorates nonalcoholic steatohepatitis and related metabolic disorders in mice.
Kim KH; Kim SH; Han DH; Jo YS; Lee YH; Lee MS
Sci Rep; 2018 May; 8(1):6789. PubMed ID: 29717162
[TBL] [Abstract][Full Text] [Related]
9. Targeting NFATc4 attenuates non-alcoholic steatohepatitis in mice.
Du M; Wang X; Yuan L; Liu B; Mao X; Huang D; Yang L; Huang K; Zhang F; Wang Y; Luo X; Wang C; Peng J; Liang M; Huang D; Huang K
J Hepatol; 2020 Dec; 73(6):1333-1346. PubMed ID: 32717288
[TBL] [Abstract][Full Text] [Related]
10. Inhibiting Interleukin 11 Signaling Reduces Hepatocyte Death and Liver Fibrosis, Inflammation, and Steatosis in Mouse Models of Nonalcoholic Steatohepatitis.
Widjaja AA; Singh BK; Adami E; Viswanathan S; Dong J; D'Agostino GA; Ng B; Lim WW; Tan J; Paleja BS; Tripathi M; Lim SY; Shekeran SG; Chothani SP; Rabes A; Sombetzki M; Bruinstroop E; Min LP; Sinha RA; Albani S; Yen PM; Schafer S; Cook SA
Gastroenterology; 2019 Sep; 157(3):777-792.e14. PubMed ID: 31078624
[TBL] [Abstract][Full Text] [Related]
11. Myeloperoxidase-Hepatocyte-Stellate Cell Cross Talk Promotes Hepatocyte Injury and Fibrosis in Experimental Nonalcoholic Steatohepatitis.
Pulli B; Ali M; Iwamoto Y; Zeller MW; Schob S; Linnoila JJ; Chen JW
Antioxid Redox Signal; 2015 Dec; 23(16):1255-69. PubMed ID: 26058518
[TBL] [Abstract][Full Text] [Related]
12. Notch activity characterizes a common hepatocellular carcinoma subtype with unique molecular and clinicopathologic features.
Zhu C; Ho YJ; Salomao MA; Dapito DH; Bartolome A; Schwabe RF; Lee JS; Lowe SW; Pajvani UB
J Hepatol; 2021 Mar; 74(3):613-626. PubMed ID: 33038431
[TBL] [Abstract][Full Text] [Related]
13. Fucoxanthin inhibits hepatic oxidative stress, inflammation, and fibrosis in diet-induced nonalcoholic steatohepatitis model mice.
Takatani N; Kono Y; Beppu F; Okamatsu-Ogura Y; Yamano Y; Miyashita K; Hosokawa M
Biochem Biophys Res Commun; 2020 Jul; 528(2):305-310. PubMed ID: 32475638
[TBL] [Abstract][Full Text] [Related]
14. Notch-mediated hepatocyte MCP-1 secretion causes liver fibrosis.
Kang J; Postigo-Fernandez J; Kim K; Zhu C; Yu J; Meroni M; Mayfield B; Bartolomé A; Dapito DH; Ferrante AW; Dongiovanni P; Valenti L; Creusot RJ; Pajvani UB
JCI Insight; 2023 Feb; 8(3):. PubMed ID: 36752206
[TBL] [Abstract][Full Text] [Related]
15. Nobiletin mitigates hepatocytes death, liver inflammation, and fibrosis in a murine model of NASH through modulating hepatic oxidative stress and mitochondrial dysfunction.
Li S; Li X; Chen F; Liu M; Ning L; Yan Y; Zhang S; Huang S; Tu C
J Nutr Biochem; 2022 Feb; 100():108888. PubMed ID: 34695558
[TBL] [Abstract][Full Text] [Related]
16. Mechanisms of Fibrosis Development in Nonalcoholic Steatohepatitis.
Schwabe RF; Tabas I; Pajvani UB
Gastroenterology; 2020 May; 158(7):1913-1928. PubMed ID: 32044315
[TBL] [Abstract][Full Text] [Related]
17. Imaging Fibrogenesis in a Diet-Induced Model of Nonalcoholic Steatohepatitis (NASH).
Hartimath SV; Boominathan R; Soh V; Cheng P; Deng X; Chong YC; Yong FF; Tan PW; Han W; Robins EG; Goggi JL
Contrast Media Mol Imaging; 2019; 2019():6298128. PubMed ID: 31866798
[TBL] [Abstract][Full Text] [Related]
18. A Functional Role of GAS6/TAM in Nonalcoholic Steatohepatitis Progression Implicates AXL as Therapeutic Target.
Tutusaus A; de Gregorio E; Cucarull B; Cristóbal H; Aresté C; Graupera I; Coll M; Colell A; Gausdal G; Lorens JB; García de Frutos P; Morales A; Marí M
Cell Mol Gastroenterol Hepatol; 2020; 9(3):349-368. PubMed ID: 31689560
[TBL] [Abstract][Full Text] [Related]
19. Hepatic Mitochondrial SAB Deletion or Knockdown Alleviates Diet-Induced Metabolic Syndrome, Steatohepatitis, and Hepatic Fibrosis.
Win S; Min RWM; Zhang J; Kanel G; Wanken B; Chen Y; Li M; Wang Y; Suzuki A; Aung FWM; Murray SF; Aghajan M; Than TA; Kaplowitz N
Hepatology; 2021 Dec; 74(6):3127-3145. PubMed ID: 34331779
[TBL] [Abstract][Full Text] [Related]
20. Pan-caspase inhibitor VX-166 reduces fibrosis in an animal model of nonalcoholic steatohepatitis.
Witek RP; Stone WC; Karaca FG; Syn WK; Pereira TA; Agboola KM; Omenetti A; Jung Y; Teaberry V; Choi SS; Guy CD; Pollard J; Charlton P; Diehl AM
Hepatology; 2009 Nov; 50(5):1421-30. PubMed ID: 19676126
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
